Novel devimistat results in complete remissions in heavily pretreated Burkitt lymphoma in a phase 2 trial.

ABSTRACT:

Abstract

Patients with primary refractory or relapsed (R/R) MYC-driven aggressive B-cell lymphomas, such as Burkitt lymphoma (BL), plasmablastic lymphoma (PBL), and double-hit lymphoma (DHL)/triple-hit lymphoma (THL), have a dismal prognosis with few survivors. The deregulated MYC protein drives proliferation with dependence on tricarboxylic acid cycle intermediates as biosynthetic precursors. Devimistat disrupts mitochondrial production of adenosine triphosphate and biosynthetic intermediates. We conducted a phase 2 trial to explore the efficacy of devimistat in R/R-BL, R/R-PBL, and R/R-DHL, administered daily for 5 days every 14 days for 2 cycles, followed by maintenance for 5 days every 21 days until progression, toxicity, or transplant. No responses were seen in the 2 enrolled

SUBMITTER: Steiner R 

PROVIDER: S-EPMC12615278 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature